


CORRECTION OPEN



# Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Huai-liang Wu, Zi-yin Luo, Zong-lin He, Yue Gong, Miao Mo, Wai-kit Ming and Guang-yu Liu 

© The Author(s), under exclusive licence to Springer Nature Limited 2023

*British Journal of Cancer* (2023) 128:704; <https://doi.org/10.1038/s41416-023-02159-4>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-022-02111-y>, published online 23 December 2022

The original version of this article contained a mistake. The first affiliation should be changed to Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. The original article has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s), under exclusive licence to Springer Nature Limited 2023